Literature DB >> 24144037

Meta analysis about the efficacy and safety of anti-ocular hypertension eye drops without benzalkonium chloride.

Yan-Qing Wang1, Xin Wang, Ping Liu.   

Abstract

OBJECTIVE: To explore the safety and efficacy of eye drops without benzalkonium chloride (BAK) in treating glaucoma and ocular hypertension.
METHODS: The clinical case-control literatures about eye drops without BAK treating glaucoma and ocular hypertension were retrieved in PubMed, EMBASE, Cochrane and Chinese Biological and Medical database. Meta 5.0 software was used to analyze the literatures.
RESULTS: Five clinical control studies were included. The results indicated both eye drops could lower the intraocular pressure, and the intraocular pressure-lowering difference between two eye drops was 0.07 mmHg (95% CI: 0.04, 0.19) (P>0.05). Two adverse reactions occurred more were conjunctival injection (10.78%) and allergic conjunctivitis (4.78%). The odd ratio of two eye drops occurring conjunctival injection and allergic conjunctivitis was 0.67 (95% CI, 0.25, 1.10) and 0.82 (95% CI, 0.09, 1.54), respectively (P<0.05) in fixed effect model.
CONCLUSIONS: There is no difference between the eye drops with or without BAK in lowering intraocular pressure, but the latter is of higher safety. In consideration of the relatively small sample size of this research, more high-quality clinical research contrasts are needed as evidence.
Copyright © 2013 Hainan Medical College. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Benzalkonium chloride; Eye drops; Glaucoma; Meta analysis

Mesh:

Substances:

Year:  2013        PMID: 24144037     DOI: 10.1016/S1995-7645(13)60181-9

Source DB:  PubMed          Journal:  Asian Pac J Trop Med        ISSN: 1995-7645            Impact factor:   1.226


  1 in total

Review 1.  Ocular hypotensive effects of prostaglandin analogs in Japanese patients with normal-tension glaucoma: a literature review.

Authors:  Yasutaka Takagi; Kazunori Santo; Masayo Hashimoto; Takeo Fukuchi
Journal:  Clin Ophthalmol       Date:  2018-09-21
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.